Literature DB >> 12963850

Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells.

Bing Z Carter1, Rui-Yu Wang, Wendy D Schober, Michele Milella, David Chism, Michael Andreeff.   

Abstract

Survivin, a member of inhibitor of apoptosis family of proteins, plays important roles in both cell proliferation and cell death. We previously observed that Survivin is overexpressed in leukemic cell lines and blasts from patients with acute myelogenous leukemia (AML). To understand the roles of Survivin in AML and search for new approaches to the treatment of AML, we inhibited Survivin expression in HL-60 cells with a Survivin anti-sense oligonucleotide (sur-AS-ODN) (ISIS 23722). This blocked significant numbers of HL-60 cells in G2/M phase, and halted cell proliferation at 24 hrs and progressing over time. There was only a slight increase in the number of apoptotic cells at 24 hrs compared with cells treated with nonsense oligonucleotide (NS-ODN). At 48 hrs, however, there were significant increases in sub-G1 phase and annexin V+ cells, suggesting that cell division defects caused cell death. This was supported by the finding that a reduction in the Survivin protein by sur-AS-ODN in cells under serum-free medium did not induce G2/M block and cell death compared to cells treated with NS-ODN. The formation of polyploid cells was observed 48 hrs after sur-AS-ODN treatment, as was the activation of caspase 3, which suggested that apoptotic cell death had occurred. The mitochondrial release of cytochrome C and Smac and the nuclear translocation of the apoptosis-inducing factor were also detected. Our results suggest that Survivin is essential for cell cycle progression in leukemic cells. Reduced Survivin expression causes a cell-cycle defect that leads to cell death through a mitochondrial pathway. This finding has potential utility for therapy of patients with AML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963850

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

Review 2.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

3.  Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.

Authors:  Bing Z Carter; Yihua Qiu; Xuelin Huang; Lixia Diao; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Gordon B Mills; Michael Andreeff; Steven M Kornblau
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

4.  Prognostic significance of survivin in pediatric acute lymphoblastic leukemia.

Authors:  Asmaa M Esh; Maha Atfy; Nashwa A Azizi; Mohamed M El Naggar; Ebtesam E Khalil; Layla Sherief
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-12       Impact factor: 0.900

5.  Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Maria Cabreira-Hansen; Miloslav Beran; Teresa McQueen; Wenjing Chen; Michael Andreeff
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

6.  Evaluating the expression level of Survivin gene in different groups of B-cell acute lymphoblastic leukemia patients of Iran.

Authors:  Mahan Mohammadi; Farzane Amirmahani; Kiarash Jamshidi Goharrizi; Rambod Pakzad; Hossein Dolat
Journal:  Mol Biol Rep       Date:  2019-04-30       Impact factor: 2.316

7.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

8.  Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Authors:  Harry P Erba; Hamid Sayar; Mark Juckett; Michael Lahn; Valerie Andre; Sophie Callies; Shelly Schmidt; Sunil Kadam; John T Brandt; Dirk Van Bockstaele; Michael Andreeff
Journal:  Invest New Drugs       Date:  2013-02-10       Impact factor: 3.850

9.  Inhibition of DNA primase and induction of apoptosis by 3,3'-diethyl-9-methylthia-carbocyanine iodide in hepatocellular carcinoma BEL-7402 cells.

Authors:  Zhi-Ming Li; Zong-Chao Liu; Zhong-Zhen Guan; Xiao-Feng Zhu; Jun-Min Zhou; Bing-Fen Xie; Gong-Kan Feng; Zhen-Yu Zhu; Wen-Qi Jiang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 10.  Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.

Authors:  Eric Goethe; Bing Z Carter; Ganesh Rao; Naveen Pemmaraju
Journal:  J Neurooncol       Date:  2017-12-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.